Earnings Releases·Nov 6, 2026, 4:15 PM ET

Entera Bio Ltd. — Third Quarter 2026 Earnings Summary

Reported a net loss of $15.6 million ($0.11 per share) for Q3 2026, compared to $3.2 million ($0.07 per share) in the prior year period, driven primarily by a $7.5 million non-cash fair value remeasurement of pre-funded warrants and increased R&D expenses to $4.9 million.
Completed an oversubscribed private placement in July 2026 raising approximately $275.0 million in gross proceeds, resulting in total cash and cash equivalents of $265.9 million as of September 30, 2026.
Cash resources are sufficient to fund the EB613 Phase 3 registrational program through topline results and NDA submission, with first site activation expected in late 2026 and topline results anticipated in the second half of 2028.
Expanded leadership and board teams with key appointments in clinical development and governance, while the FDA accepted the proposed registrational development plan for EB613 in June 2026.
No revenue was generated in the quarter, with the company transitioning into late-stage clinical execution mode for its lead asset, EB613, an oral anabolic treatment for osteoporosis.